Business Wire

Techstars Announces Two New Executive Team Leaders: Rupa Athreya Appointed Chief Accelerator Investments Officer & Marie Moussavou Appointed Chief Portfolio Services Officer

6.1.2022 16:00:00 EET | Business Wire | Press release

Share

Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, has created two new leadership roles as the company continues to scale to serve more founders around the world. With $850 million in assets under management, 47 accelerator programs in 17 countries, and a global alumni base of more than 2,700 companies, both roles will provide strategic and operational support to thousands of entrepreneurs. Athreya and Moussavou will report directly to the company’s CEO, Maelle Gavet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005289/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Newly appointed Chief Accelerator Investments Officer Rupa Athreya (Photo: Business Wire)

“Techstars has an unprecedented ability to impact entrepreneurs through our unique pre-seed investment model that identifies exceptional entrepreneurs worldwide and supports them operationally and financially as they build their businesses,” stated Gavet. “We count on globally experienced executives with the ability to think big-picture, enabling the organization to operate at scale which is why both Marie and Rupa are such wonderful additions to our global management team.”

As the company’s first Chief Accelerator Investments Officer, Rupa Athreya will lead a worldwide team of more than 75 investment professionals who represent Techstars in 37 cities around the world. Techstars operates under the principle that the best founders can come from anywhere, running programs locally in the cities where the entrepreneurs operate or seek to grow. Techstars maintains a small class size ranging from 10 to 12 portfolio companies and runs multiple programs in cities with larger entrepreneur ecosystems. Techstars’ Accelerator Investment Team invested approximately $94 million last year and will continue to grow its portfolio as investors around the world seek to invest in viable early-stage companies. Overseeing this decentralized approach requires a seasoned executive with a strategic mindset, strong operational skills and global experience.

Having worked at global firms such as OppenheimerFunds, JPMorgan Chase, Bloomberg and McKinsey, Athreya has most recently been an independent consultant advising startups and new businesses as well as global financial institutions on strategy, innovation, and go-to-market execution. She has close to 20 years of expertise in building and launching new businesses and products, having led product development at OppenheimerFunds, founded a robo-advisor at Bloomberg and launched the Chase Private Client business at JPMorgan Chase. She has a Ph.D. in Economics from Yale University, a B.A. in Philosophy, Politics and Economics from Oxford University and a B.A. in Economics from the University of Delhi. She will continue to be based out of New York, NY.

As Techstars’ first Chief Portfolio Services Officer, Marie Moussavou will be responsible for advancing growth, providing infrastructure support and investment opportunities for Techstars’ more than 6,500 alumni founders as they lead their companies through later stages. Portfolio Services provides capital and funding, business development and talent connections, mentorship, and knowledge exchange for Techstars’ network of founders, investors, mentors and innovation partners. With this ever-growing network, the Portfolio Services team under Moussavou’s leadership will maintain deep, personal relationships with founders while leveraging robust data management skills to offer founders customized and scalable support.

Moussavou has a proven track record of scaling high growth, customer-focused organizations through innovation and operational excellence. Most recently she worked at Amazon for 15 years in various senior roles, including Technical Advisor to the SVP for International, Director of Alexa Europe, and Director of Operations for Amazon Transportation Services Europe. Marie has an MBA from the London Business School and lives in London, U.K., where she will continue to be based.

About Techstars

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,800 companies with a combined market cap of more than $195B. www.techstars.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ali Whitman
ali.whitman@techstars.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye